Building on the success of the PD-1 inhibitor Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) in the recurrent renal cell carcinoma setting, combination regimens, including Opdivo plus Yervoy, Keytruda (Merck & Co.) plus Inlyta (Pfizer), Bavencio (Merck KGaA / Pfizer) plus Inlyta, are revolutionizing the treatment of advanced disease. Angiogenesis inhibitors such as Sutent (Pfizer), Votrient (Novartis), and Cabometyx (Exelixis / Ipsen) remain a key feature of first-line treatment. The entry and increased uptake of Cabometyx and Opdivo in this setting are beginning to shift Inlyta and Lenvima / Kisplyx (Eisai) plus Afinitor (Novartis) to later lines. Furthermore, following Sutent’s approval for high-risk early-stage (stage I-III) patients, multiple immune checkpoint inhibitors are anticipated to transition to the early-stage setting. The renal cell carcinoma therapy market remains highly competitive and dynamic, but the developer of an efficacious therapy can expect to reap high commercial rewards.
- How are the early-stage and advanced or metastatic drug-treatable renal cell carcinoma populations defined, and how will drug-treatment rates evolve over the forecast period?
- What is the current treatment landscape for renal cell carcinoma, and what are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled?
- What is the outlook for key combination regimens in renal cell carcinoma? How will these combination regimens be differentiated, and which look the most promising?
- Which emerging therapies do we forecast to enter the renal cell carcinoma market? What uptake and sales are these therapies anticipated to secure?
Geographies: United States, EU5, Japan
Primary Research: 19 country-specific interviews with thought-leading medical oncologists and urologists. Supported by survey data collected for this and other DRG research.
Epidemiology: Diagnosed and recurrent incidence of renal cell carcinoma by country, segmented by drug-treatable and -treated early-stage and locally advanced or metastatic disease and line of therapy.
Forecast: 10-year, annualized, drug-level sales and patient share of key renal cell carcinoma therapies through 2029, segmented by brands/generics and epidemiological subpopulations.
Emerging Therapies: Phase III/PR: 7 drugs; Phase II: 9 drugs; coverage of select preclinical and Phase I products.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.